Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will present updated Phase 1 FIT-001 data showing that darlifarnib combined with cabozantinib produced encouraging clinical activity and a manageable safety profile in advanced clear cell renal cell carcinoma patients previously treated with cabozantinib.
The presentation is scheduled for April 17, 2026 at IKCS Europe 2026; a virtual investor webcast and replay will follow at 7:30 a.m. PT / 10:30 a.m. ET.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – KURA
On the day this news was published, KURA gained 0.68%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers like AVBP, GERN and SANA showed negative moves (e.g., GERN -5.52%), but no peers appeared in the momentum scanner, pointing to a stock-specific setup rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 06 | Inducement option grants | Neutral | +5.3% | Reported new employee inducement stock options totaling 44,700 shares. |
| Mar 05 | Earnings and update | Neutral | -0.5% | Released Q4 and full-year 2025 results and pipeline progress update. |
| Feb 26 | Earnings date notice | Neutral | +1.1% | Announced date and time for Q4 and full-year 2025 results call. |
| Feb 25 | Investor conferences | Neutral | +2.1% | Detailed participation in multiple March 2026 healthcare conferences. |
| Feb 06 | Inducement option grants | Neutral | +5.8% | Disclosed inducement stock options for new employees totaling 69,750 shares. |
Recent news flow has centered on routine corporate items (inducement grants, conferences, earnings), with several instances of positive single-day moves following such updates.
Over the last few months, Kura’s news has focused on corporate housekeeping and financial reporting. Inducement option grants on Feb 6 and Mar 6, 2026 coincided with single-day gains above 5%. The Mar 5, 2026 Q4 and full-year 2025 results, highlighting initial KOMZIFTI revenue and a strong cash position, saw only a modest -0.47% move. Conference participation and an earnings-date announcement in late February drew small positive reactions, framing today’s clinical-data update within an already active communication cadence.
Market Pulse Summary
This announcement highlights updated Phase 1 data from the FIT-001 trial of darlifarnib (KO-2806) plus cabozantinib in clear cell renal cell carcinoma, to be presented at IKCS Europe 2026 and discussed on an investor call on April 17, 2026. It builds on encouraging activity and safety reported at ESMO 2025. Investors may watch for consistency of response, durability, and safety in patients previously treated with cabozantinib, as well as clarity on next trial steps and combination strategies.
Key Terms
farnesyl transferase inhibitor medical
vegfr tki therapy medical
clear cell renal cell carcinoma medical
ccrcc medical
phase 1 medical
vegfr medical
tki medical
AI-generated analysis. Not financial advice.
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy
Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST
SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France.
The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology (ESMO) Congress, where the combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile in patients with advanced renal cell carcinoma.
IKCS Europe 2026 Presentation Details
Title: Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo: Preliminary Phase 1 results from FIT-001
Abstract Session: 7
Date: April 17, 2026
Time: 3:30 p.m. – 4:30 p.m. CEST
Virtual Investor Event
Kura will host a webcast and conference call on April 17, 2026, at 7:30 am PT / 10:30 am ET / 4:30 pm CEST featuring management and a clinical investigator from the darlifarnib program. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.
About darlifarnib
Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling. This mechanism has potential to enhance the activity of multiple targeted therapies, including VEGFR-targeted therapies such as cabozantinib.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding Kura’s presentation of FIT-001 data at IKCS Europe 2026, the therapeutic potential of the combination of darlifarnib and cabozantinib in patients with clear cell renal cell carcinoma, and the potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy and to enhance the activity of multiple targeted therapies. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
